1. Home
  2. MURA vs SPCB Comparison

MURA vs SPCB Comparison

Compare MURA & SPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • SPCB
  • Stock Information
  • Founded
  • MURA 2013
  • SPCB 1988
  • Country
  • MURA Ireland
  • SPCB Israel
  • Employees
  • MURA N/A
  • SPCB N/A
  • Industry
  • MURA
  • SPCB Semiconductors
  • Sector
  • MURA
  • SPCB Technology
  • Exchange
  • MURA Nasdaq
  • SPCB Nasdaq
  • Market Cap
  • MURA 45.8M
  • SPCB 53.3M
  • IPO Year
  • MURA N/A
  • SPCB N/A
  • Fundamental
  • Price
  • MURA $2.46
  • SPCB $10.42
  • Analyst Decision
  • MURA Strong Buy
  • SPCB Strong Buy
  • Analyst Count
  • MURA 4
  • SPCB 1
  • Target Price
  • MURA $13.00
  • SPCB $18.00
  • AVG Volume (30 Days)
  • MURA 106.6K
  • SPCB 213.2K
  • Earning Date
  • MURA 08-12-2025
  • SPCB 08-14-2025
  • Dividend Yield
  • MURA N/A
  • SPCB N/A
  • EPS Growth
  • MURA N/A
  • SPCB N/A
  • EPS
  • MURA N/A
  • SPCB 1.89
  • Revenue
  • MURA N/A
  • SPCB $27,831,000.00
  • Revenue This Year
  • MURA N/A
  • SPCB $2.73
  • Revenue Next Year
  • MURA N/A
  • SPCB $22.87
  • P/E Ratio
  • MURA N/A
  • SPCB $5.51
  • Revenue Growth
  • MURA N/A
  • SPCB 2.90
  • 52 Week Low
  • MURA $0.95
  • SPCB $2.55
  • 52 Week High
  • MURA $4.74
  • SPCB $18.95
  • Technical
  • Relative Strength Index (RSI)
  • MURA 44.84
  • SPCB 56.38
  • Support Level
  • MURA $2.51
  • SPCB $9.46
  • Resistance Level
  • MURA $2.66
  • SPCB $11.18
  • Average True Range (ATR)
  • MURA 0.09
  • SPCB 1.01
  • MACD
  • MURA -0.02
  • SPCB -0.15
  • Stochastic Oscillator
  • MURA 20.08
  • SPCB 45.13

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About SPCB SuperCom Ltd. (Israel)

SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.

Share on Social Networks: